High-throughput single-сell sequencing in cancer research | Signal ...
12-year-old With Extremely Rare Brain Cancer To Undergo Clinical Trial At CHLA In Hopes Of Recovery
12-year-old with rare brain cancer to undergo clinical trial at CHLA
SHARE
SHARE
TWEET
SHARE
What to watch next
Disneyland dedicates 3 windows on Main Street to Make-A-Wish
ABC 7 Los Angeles
Pasadena's Father Nature Lavash Bistro offers tasty healthy options
ABC 7 Los Angeles
Los Angeles bids farewell to former Mayor Richard Riordan
ABC 7 Los Angeles
Suspect arrested after stolen forklift is taken on wild ride in OC
ABC 7 Los Angeles
Suspect arrested after stolen forklift is taken on wild ride in OC
ABC 7 Los Angeles
Memorial service planned for teen killed near Westlake High School
ABC 7 Los Angeles
Video shows fight at WeHo intersection as security ambassadors look on
ABC 7 Los Angeles
Burglars hit Westwood businesses in string of 5 overnight break-ins
ABC 7 Los Angeles
Fetus with umbilical cord found near trash can in South El Monte
ABC 7 Los Angeles
Infant dies in South El Monte, LASD investigation underway
ABC 7 Los Angeles
Burglars hit Westwood businesses in string of overnight break-ins
ABC 7 Los Angeles
Long Beach reports 4.6% jump in homelessness in annual count
ABC 7 Los Angeles
Duck with arrow shot through neck to be released from hospital Friday
ABC 7 Los Angeles
Sunshine, warm temps on tap in SoCal Friday ahead of hot weekend
ABC 7 Los Angeles
Landslide damages Casa Romantica in San Clemente, halts rail service
ABC 7 Los Angeles
Khris Davis stars in heavyweight story 'Big George Foreman'
ABC 7 Los AngelesClick to expand
UP NEXT
Brain cancer is complicated and tricky. Despite years of research, survival rates have remained bleak while those of other cancers have significantly improved. The situation is even harsher for young patients.
Twelve-year-old Jaxon Toner is a straight-A student with a black belt in Taekwondo. But in December, he started to struggle with the left side of his body.
"I couldn't clench my toes. My left arm was weak," Toner said.
"We went straight to the ER because I thought he was having a stroke," said his mother Jennifer Toner.
A brain scan revealed a parent's worst nightmare: a rare pediatric brain cancer called diffuse hemispheric glioma. It was in Grade 4.
"It's listed as an H3-G34R. It's very rare. Only 7,000 kids in the world have this. The prognosis is very poor. It's about 13 months for children," Jennifer Toner said.
It's a road few patients have traveled. Jaxon is receiving chemo and radiation and hopes to start a clinical trial in which doctors at Children's Hospital Los Angeles will use Car T-cell therapy to super charge his immune cells to fight the cancer.
"We're definitely on the attack. There is a lot of research going on out there. Unfortunately, there's not enough of it," said David Arons, CEO of the National Brain Tumor Society. About 700,000 Americans are living with brain cancer, but those numbers aren't enough to garner the attention and funding needed to find more treatments for brain tumors.
"When someone gets one. They need state-of-the-art treatment. They need clinical trials. They need the best of the best right away. And so we wish there was a lot more money going into research," said Arons.
"We're looking for any help and guidance. A doctor to ride in on his white horse and save the day," said Jennifer Toner.
For Jaxon Toner, his situation is tough but he says he doesn't let it bother him.
"I don't let it bother me," Jaxon Toner said.
Jaxon Toner strives to make the most of every day. This Saturday, his family is supporting the Southern California Brain Tumor Walk and Race in Griffith Park. He believes getting others involved is his best hope.
"This is scary. People should definitely help," Jaxon Toner said.
Jaxon Toner's friends and family have set up a GoFundMe in support of his battle with the disease.
This Gel Stops Brain Tumors After Surgery, Offering Hope For Glioblastoma Cancer Patients
Johns Hopkins / SWNS Medication delivered by a novel gel cured 100% of mice with an aggressive brain cancer, a striking result that offers new hope for patients diagnosed with glioblastoma, one of the deadliest and most common brain tumors in humans.
"We think this hydrogel will be the future," said study leader Professor Honggang Cui of Johns Hopkins University.
Cui's team combined an anticancer drug and an antibody in a solution that self-assembles into a gel to fill the tiny grooves left after a brain tumor is surgically removed.
The gel can reach areas that surgery might miss and current drugs struggle to reach to kill lingering cancer cells and suppress tumor growth.
The gel also seems to trigger an immune response that a mouse's body struggles to activate on its own when fighting glioblastoma.
When the researchers re-challenged surviving mice with a new glioblastoma tumor, their immune systems alone beat the cancer without additional medication. The gel appears to not only fend off cancer but help rewire the immune system to discourage recurrence with immunological memory, researchers said.
CHECK OUT: Vaccine that Could Cure and Even Prevent Brain Cancer Developed by Scientists
Still, surgery is essential for this approach, the researchers said. Applying the gel directly in the brain without surgical removal of the tumor resulted in just a 50% survival rate.
"The surgery likely alleviates some of that pressure and allows more time for the gel to activate the immune system to fight the cancer cells," Prof. Cui said.
The gel solution consists of nano-sized filaments made with paclitaxel, an FDA-approved drug for breast, lung, and other cancers. The filaments provided a vehicle to deliver the antibody called aCD47. By blanketing the tumor cavity evenly, the gel releases medication steadily over several weeks, and its active ingredients remain close to the injection site.
By using that specific antibody, the team is trying to overcome one of the toughest hurdles in glioblastoma research. It targets macrophages, a type of cell that sometimes supports immunity but other times protects cancer cells, allowing aggressive tumor growth.
MORE WINS: New Brain Cancer Immunotherapy Shows Promise in Human Trial – Most Patients Saw No Tumor Growth
The results are published in Proceedings of the National Academy of Sciences.
One of the go-to therapies for glioblastoma is a wafer co-developed by a team of researchers at Johns Hopkins and the Massachusetts Institute of Technology in the 1990s, commercially known as Gliadel. It is an FDA-approved, biodegradable polymer that also delivers medication into the brain after surgical tumor removal.
Gliadel showed significant survival rates in laboratory experiments, but the results achieved with the new gel are some of the most impressive the Johns Hopkins team has seen, said Betty Tyler, a co-author and associate professor of neurosurgery at the Johns Hopkins School of Medicine who played a pivotal role in the development of Gliadel.
"We don't usually see 100% survival in mouse models of this disease," Tyler said. "Thinking that there is potential for this new hydrogel combination to change that survival curve for glioblastoma patients is very exciting."
HEARTWARMING: Mom Wins Lottery with Ticket She Bought Celebrating Daughter's Victory Over Cancer
The new gel offers hope for future glioblastoma treatment because it integrates anticancer drugs and antibodies, a combination of therapies researchers say is difficult to administer simultaneously because of the molecular composition of the ingredients.
"The gel is implanted at the time of tumor resection, which makes it work really well," Tyler said.
The challenge now is to translate the gel's results in the lab into therapies with substantial clinical impacts.
DON'T FORGET TO SHARE THE HOPE ON SOCIAL MEDIA….
New Gel Treatment Wipes Out Deadly Brain Cancer In Mice – Offers Hope For Defeating Glioblastoma In Humans
Summary: Combining an anticancer drug with an antibody, researchers developed a novel gel that cured glioblastoma brain cancer in 100% of mouse models. The findings offer new hope in the fight against the most deadly form of brain cancer in humans. The gel triggers an immune response and, when the cancer was reintroduced, the immune system alone helped beat the cancer without additional medications.
Source: Johns Hopkins University
Medication delivered by a novel gel cured 100% of mice with an aggressive brain cancer, a striking result that offers new hope for patients diagnosed with glioblastoma, one of the deadliest and most common brain tumors in humans.
"Despite recent technological advancements, there is a dire need for new treatment strategies," said Honggang Cui, a Johns Hopkins University chemical and biomolecular engineer who led the research.
"We think this hydrogel will be the future and will supplement current treatments for brain cancer."
Cui's team combined an anticancer drug and an antibody in a solution that self-assembles into a gel to fill the tiny grooves left after a brain tumor is surgically removed. The gel can reach areas that surgery might miss and current drugs struggle to reach to kill lingering cancer cells and suppress tumor growth.
The results are published today in Proceedings of the National Academy of Sciences.
The gel also seems to trigger an immune response that a mouse's body struggles to activate on its own when fighting glioblastoma. When the researchers rechallenged surviving mice with a new glioblastoma tumor, their immune systems alone beat the cancer without additional medication.
The gel appears to not only fend off cancer but help rewire the immune system to discourage recurrence with immunological memory, researchers said.
Still, surgery is essential for this approach, the researchers said. Applying the gel directly in the brain without surgical removal of the tumor resulted in a 50% survival rate.
"The surgery likely alleviates some of that pressure and allows more time for the gel to activate the immune system to fight the cancer cells," Cui said.
The gel solution consists of nano-sized filaments made with paclitaxel, an FDA-approved drug for breast, lung, and other cancers. The filaments provide a vehicle to deliver an antibody called aCD47. By blanketing the tumor cavity evenly, the gel releases medication steadily over several weeks, and its active ingredients remain close to the injection site.
By using that specific antibody, the team is trying to overcome one of the toughest hurdles in glioblastoma research. It targets macrophages, a type of cell that sometimes supports immunity but other times protects cancer cells, allowing aggressive tumor growth.
One of the go-to therapies for glioblastoma is a wafer co-developed by a team of researchers at Johns Hopkins and the Massachusetts Institute of Technology in the 1990s, commercially known as Gliadel. It is an FDA-approved, biodegradable polymer that also delivers medication into the brain after surgical tumor removal.
Gliadel showed significant survival rates in laboratory experiments, but the results achieved with the new gel are some of the most impressive the Johns Hopkins team has seen, said Betty Tyler, a co-author and associate professor of neurosurgery at the Johns Hopkins School of Medicine who played a pivotal role in the development of Gliadel.
"We don't usually see 100% survival in mouse models of this disease," Tyler said. "Thinking that there is potential for this new hydrogel combination to change that survival curve for glioblastoma patients is very exciting."
The gel also seems to trigger an immune response that a mouse's body struggles to activate on its own when fighting glioblastoma. Image is in the public domain The new gel offers hope for future glioblastoma treatment because it integrates anticancer drugs and antibodies, a combination of therapies researchers say is difficult to administer simultaneously because of the molecular composition of the ingredients.
"This hydrogel combines both chemotherapy and immunotherapy intracranially," Tyler said. "The gel is implanted at the time of tumor resection, which makes it work really well."
Johns Hopkins co-author Henry Brem, who co-developed Gliadel in addition to other brain tumor therapies currently in clinical trials, emphasized the challenge of translating the gel's results in the lab into therapies with substantial clinical impacts.
"The challenge to us now is to transfer an exciting laboratory phenomenon to clinical trials," said Brem, who is neurosurgeon-in-chief at Johns Hopkins Hospital.
Other Johns Hopkins authors are Feihu Wang, Qian Huang, Hao Su, Mingjiao Sun, Zeyu Wang, Ziqi Chen, Mengzhen Zheng, Rami W. Chakroun, Maya K. Monroe, Daiqing Chen, Zongyuan Wang, Noah Gorelick, Riccardo Serra, Han Wang, Yun Guan, Jung Soo Suk, and Justin Hanes.
Author: Roberto MolarSource: Johns Hopkins UniversityContact: Roberto Molar – Johns Hopkins UniversityImage: The image is in the public domain
Original Research: The findings will appear in PNAS
Comments
Post a Comment